Dr. Meyer joined uniQure as Chief Medical Officer in 2013. He is an experienced biopharma executive with more than 20 years of extensive Clinical Research, Regulatory Affairs, Medical Affairs and Pharmacovigilance background and with profound experience in all phases of pharmaceutical R&D of small molecules, biologics and gene therapy products. In addition, he has extensive R&D executive experience with an international track record of successfully building Development units and secures value generation in the transition phase from R&D through Clinical Development and Commercialization. Dr. Meyer brings his experience from both biotechnology companies and large pharmas in Scandinavia with particular expertise in the Development of treatments for rare diseases.Dr. Meyer joined uniQure from Cardoz AB where he spent three years as Chief Medical Officer. From 2006 to 2010, Dr. Meyer held leadership positions in Clinical Development at Symphogen A/S, where he was Senior Vice President for Medical Affairs and Vice President, Clinical Development. Prior to Symphogen, he played an important role in Clinical Development at Zymenex A/S and spent five years in Clinical Development at Novo Nordisk A/S. Dr. Meyer received both his M.D. and Ph.D. degrees from the University of Copenhagen, Denmark.
Deya Corzo, MD is best known for her successful leadership of first-in-class product development, worldwide launch and post-launch programs in the orphan diseases and oncology arenas.
Dr. Corzo led the medical team for the global development and launch of Myozyme®, the Genzyme multi-award winning enzyme replacement therapy for Pompe disease. Her commitment to the highest standards of patient ethics and for creating collaborative, responsive relationships within the complex global scientific, academic and regulatory communities resulted in a second BLA submission, and subsequent approval of Lumizyme®, another life-saving enzyme replacement therapy for Pompe disease. Dr. Corzo’s Medical Affairs experience includes US and global life-cycle management responsibilities for two highly successful oncology drugs: Velcade®, a first in class proteasome inhibitor developed by Millennium/Takeda for hematological cancers; and Abraxane®, an innovative formulation of paclitaxel commercialized by Celgene for solid cancers.
Dr. Corzo is double-board certified in Pediatrics and Clinical Genetics; she is an Instructor in Pediatrics at Harvard Medical School, and an active practicing physician at the Children’s Hospital Genetics Clinic in Boston.